Ascentage Pharma Group International

NASDAQ:AAPG

Biotechnology

Healthcare
$13.01 +1.78%

+$0.31 today

Market cap
$1.21B
Beta
0.65
P/E (TTM)
-8.9
EPS (TTM)
-$13.29
52W Low $16.92High $48.45

Volume 0.00M

Average 0.01M

AAPG Stock-Based Compensation

Employee pay granted in shares or options; a non-cash expense that dilutes existing shareholders.

Ascentage Pharma Group InternationalNASDAQ: AAPG

Stock-Based Compensation · Q4 FY2025 · quarter ended Dec 2025

Stock-based compensation outflow shrinks to CN¥0

Q4 FY2025 stock-based compensation was CN¥0, compared with CN¥12.19M a year earlier. Over 3 fiscal years it compounded at -1.9% a year.

Context

  • Stock-based compensation amounted to 3.7% of revenue in FY2025, up 1.6 pp from a year earlier.
  • Stock-based compensation increased in 1 of the last 3 fiscal years.
  • FY2025 was the lowest annual figure in the 4 fiscal years shown.

Sources:Cash FlowText generated from reported figures; not investment advice.

Latest quarterDec 2025
CN¥0— QoQ
Last fiscal yearDec 2025
CN¥20.87M-0.2% YoY
Stock-Based Compensation past and forecast growth by horizon
Horizon Past Forecast Difference
Quarter-100.0%——
1 year-0.2%——
3-year CAGR-1.9%——
5-year CAGR——
10-year CAGR——

Stock-Based Compensation history

CNY · from the cash flow

Latest · FY2025
20.87M CNY
Year-over-year change
-0.2%
4-year CAGR
-18.4%

Stock-Based Compensation vs competitors

How AAPG compares with its peers on the latest reported figures

  • Peers report in different currencies, so stock-based compensation is compared through growth and share of revenue rather than absolute size.
  • Its year-over-year change of -0.2% is the 6th highest of 10, against a peer median of +8.7%.
  • Stock-based compensation amounts to 3.7% of revenue for AAPG, versus a peer median of 19.5%.
AAPG Competitors
Stock-Based Compensation for AAPG and competitors
Company Period LTM YoY 3-year CAGR% of revenue
TNGXTango Therapeutics, Inc.LTM Sep 2026$58.58M USD+109.9%+22.9%—
ZLABZai Lab LimitedLTM Jun 2026$58.29M USD-12.7%+2.3%13.0%
IDYAIDEAYA Biosciences, Inc.LTM Mar 2026$50.41M USD+30.4%+58.3%22.4%
NRIXNurix Therapeutics, Inc.LTM Aug 2026$40.66M USD+8.7%+10.5%5.8%
AAPGAscentage Pharma Group InternationalFY2025CN¥20.87M CNY-0.2%-1.9%3.7%
NUVBNuvation Bio Inc.LTM Jun 2026$19.89M USD-153.0%+30.1%11.7%
CCCCC4 Therapeutics, Inc.LTM Mar 2026$16.26M USD-43.8%-14.0%46.7%
AVBPArriVent BioPharma, Inc. Common StockLTM Mar 2026$15.73M USD+224.1%+209.1%—
VSTMVerastem, Inc.LTM Mar 2026$9.66M USD+26.4%+15.9%19.5%
ANLAdlai Nortye Ltd.LTM Jun 2024$1.94M USD——29.9%
IMRXImmuneering CorporationLTM Mar 2026$1.52M USD-69.5%——
Peer median (excluding AAPG) —+8.7%+19.4%19.5%

Competitors are the stored peer set for AAPG. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.

Cash Flow Statement

CNY
Metric
FY2021
Dec 2021
FY2022
Dec 2022
FY2023
Dec 2023
FY2024
Dec 2024
FY2025
Dec 2025
Net Income(832.25M)(887.17M)(932.86M)(395.26M)(1.24B)
Depreciation & Amortization28.33M62.92M93.2M93.17M86.48M
Deferred Income Tax00000
Stock-Based Compensation46.97M22.11M31.5M20.92M20.87M
Change in Working Capital(74.91M)104.41M(9.15M)110.97M(143.5M)
Accounts Receivables(53.97M)(388K)(91.54M)62.75M(169.8M)
Inventory(3.93M)(5.52M)(6.72M)9.57M(26.2M)
Accounts Payables024.7M(23.11M)19.52M14.77M
Other Working Capital(17.01M)85.62M112.22M19.13M37.72M
Other Non-Cash Items227.18M43.82M91.23M58.84M98.07M
Operating Cash Flow(604.68M)(653.92M)(726.08M)(111.36M)(1.17B)
Capital Expenditures(436.63M)(236.96M)(56.84M)(24.29M)(27.57M)
Acquisitions (Net)(36.2M)(20M)(20M)(25.52M)(43.34M)
Purchases of Investments(1.78B)(130M)0(312.23M)(929.14M)
Sales of Investments1.79B0000
Other Investing Activities(879K)(31.32M)88.03M(312.23M)0
Investing Cash Flow(466.52M)(384.61M)21.92M(362.04M)(1B)
Debt Repayment548.59M695.87M(13.36M)(145.34M)307.26M
Common Stock Issued1.3B0470.08M533.94M2.3B
Common Stock Repurchased(25.87M)(26.78M)(5.92M)0(9.04M)
Dividends Paid00000
Other Financing Activities(41.97M)(49.83M)(82.05M)(73.83M)(63.04M)
Financing Cash Flow1.78B619.27M368.75M314.77M2.54B
Effect of Forex Changes(23.28M)58.01M27.81M13.68M(63.24M)
Net Change in Cash686.91M(361.25M)(307.59M)(144.95M)302.68M
Free Cash Flow(1.04B)(890.88M)(782.92M)(135.65M)(1.2B)

Ascentage Pharma Group International

NASDAQ:AAPG

Intrinsic Alpha fair value

Locked

Current Price

$13.01

Margin of safety hidden

Unlock the intrinsic value to see where the current price sits on the valuation runway.

Valuation runway

Locked

Get the intrinsic value and margin of safety with a free account.